Iksuda Therapeutics Revenue and Competitors

Iksuda Therapeutics is creating next-generation, class leading Antibody-Drug Conjugates (ADCs). Our ADCs target difficult-to-treat cancers, including those that are resistant or refractory to current therapies. We are building a pipeline of ADCs centred on: • PermaLink® – proprietary conjugation chemistry for improved ADC stability • Novel ultra-potent toxins for improved tumour killing • Novel antibodies targeted towards well-selected antigens associated primarily with solid tumours We are focused on providing more effective treatments for patients who have few options, with a particular focus on solid tumours such as lung, ovarian, cervix, pancreatic and colorectal. Our first wave ADC programmes include antibodies with proven premise in ADC formats and novel DNA damaging payloads. We are working with leading research institutions in the US and Europe to develop exciting new therapies for the future. We are flexible in our approach to collaboration and welcome discussions with research groups who have novel ADC-relevant programmes. We have developed a series of high-value ADC assets, which are available for collaborative research and license.